Artificial intelligence is rapidly transforming healthcare, moving beyond the early hype into a phase of tangible, real-world impact. As we enter 2026, the global AI in healthcare market continues its remarkable growth trajectory, projected to reach nearly $187 billion by 2030. But beyond the numbers, what matters most is how AI is reshaping patient care, clinical workflows, and medical research across the globe.
AI Scribes and Clinical Documentation
One of the most visible breakthroughs has been the widespread adoption of AI scribes – tools that automatically transcribe and summarize patient-clinician conversations. This category generated $600 million in revenue in 2025, with studies showing a reduction of up to 80% in time spent on administrative tasks. For clinicians burdened by documentation, this translates to an average of three hours saved per week, time that can be redirected to direct patient care.
Diagnostics and Imaging
AI-powered diagnostics continue to push boundaries. Researchers have developed models capable of diagnosing coronary microvascular dysfunction from a standard 10-second EKG strip, a condition that previously required expensive imaging or invasive procedures. In radiology, multimodal AI models are delivering significantly higher accuracy for X-ray and pathology interpretation, generating clinic-ready reports and supporting faster clinical decision-making.
Drug Discovery Accelerated
The pharmaceutical industry is experiencing its own AI revolution. Multiple AI-designed drug candidates are advancing through clinical trials, targeting conditions such as ALS, autoimmune diseases, and various forms of cancer. Researchers have also used AI to design novel molecules that boost the effectiveness of chemotherapy for pancreatic cancer by targeting specific resistance mechanisms. AI-driven drug discovery is projected to save the industry $150 billion by 2026.
The European Regulatory Landscape
In Europe, the regulatory framework for AI in healthcare is maturing rapidly. The EU AI Act, which entered into force in phases from February 2025, classifies AI systems intended for medical use as high-risk, requiring compliance with strict standards for data quality, risk mitigation, transparency, and human oversight. The European Commission’s Apply AI Strategy, published in October 2025, further accelerates sectoral AI adoption, with healthcare-specific actions including a European Network of Expertise on AI Deployment in Healthcare planned for 2027, and an AI drug discovery challenge launching in late 2026. The European Health Data Space (EHDS), now in force, empowers individuals to control their health data and facilitates cross-border data exchange for improved care delivery.
Looking Ahead: Agentic AI and Beyond
Perhaps the most exciting frontier is the emergence of agentic AI systems – autonomous tools that can orchestrate complex clinical workflows, integrate multimodal patient data, track progress, and proactively coordinate care. Experts predict that by late 2026, these systems will begin appearing in imaging-heavy specialties like radiology and pathology, marking a shift from single-purpose AI tools to intelligent clinical assistants.
As AI in healthcare transitions from experimentation to validated clinical practice, the emphasis is increasingly on governance, data quality, and human-centered design. For projects like AI2MED, this evolving landscape reinforces the importance of equipping healthcare professionals with the AI skills and knowledge they need to harness these innovations effectively – fostering trust, modernising medical education, and ensuring that AI in medicine is adopted responsibly and to the benefit of all patients across Europe.
